People · Operator

John Landis

Named in public records as an officer, director or promoter · active 2010–2012 · Pharmaceuticals

1
Companies
2
Filings
$50.1M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Metabolic Solutions Development Co LlcPharmaceuticalsSeries B$50.1M$6.8M2010
Operator network

John Landis at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Robert Zerbe · 5 companies · 1 sharedRobert ZerbeMark Olesnavage · 4 companies · 1 sharedMark OlesnavageGerald Callahan · 3 companies · 1 sharedGerald CallahanJim Schultz · 3 companies · 1 sharedJim SchultzMichael Jandernoa · 2 companies · 1 sharedMichael JandernoaStephen Benoit · 2 companies · 1 sharedStephen BenoitWilliam Parfet · 2 companies · 1 sharedWilliam ParfetAngeline Shashlo · 1 companies · 1 sharedAngeline ShashloGerard Colca · 1 companies · 1 sharedGerard ColcaGerard R. Colca · 1 companies · 1 sharedGerard R. ColcaJames VanderLugt · 1 companies · 1 sharedJames VanderLugtRolf F. Kletzien · 1 companies · 1 sharedRolf F. KletzienRolf Kletzien · 1 companies · 1 sharedRolf KletzienSandi Doctor · 1 companies · 1 sharedSandi DoctorMetabolic Solutions Development Co Llc · $50.1M raisedMetabolic Solutions D…John LandisJL
John Landis Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside John Landis on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Robert Zerbe15
Mark Olesnavage14
Jim Schultz13
Gerald Callahan13
William Parfet12
Michael Jandernoa12
Stephen Benoit12
Sandi Doctor11
Rolf F. Kletzien11
Gerard R. Colca11
Angeline Shashlo11
Rolf Kletzien11
Gerard Colca11
James VanderLugt11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.